Réactivation d’une infection à parvovirus B19 chez une patiente infectée par le VIH

Sterpu, R.; Ichou, Houria; Mahé, Isabelle; Mortier, E.

doi:10.1016/j.revmed.2013.05.009

Cited by 7 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serology interpretation can be misleading after allogeneic HSCT, with false negative IgG and IgM, 2,17 and unlike immunocompetent patients, immunocompromised patient can also present symptomatic reactivation. [7][8][9] In general, diagnosis of viral infection after allogeneic HSCT cannot rely on serology. 18,19 Concerning hematological impairment, cytopenia are very frequent after alloHSCT and can be multifactorial, including GVHD, relapse, graft dysfunction, drug toxicity and other infections.…”

Section: Discussionmentioning

confidence: 99%

“…Although previous studies have identified DNAemia cutoff (e.g., 10 4 copies/mL) to help identify acute infection from past infection in immunocompetent patients, 16 no DNAemia cutoff has been validate in immunocompromised patients. Serology interpretation can be misleading after allogeneic HSCT, with false negative IgG and IgM, 2,17 and unlike immunocompetent patients, immunocompromised patient can also present symptomatic reactivation 7–9 . In general, diagnosis of viral infection after allogeneic HSCT cannot rely on serology 18,19 .…”

Section: Discussionmentioning

confidence: 99%

“…4,5 B19V is also known to induce pure red cell aplasia (PRCA) among patients living with chronic hemolytic diseases. 6 B19V can also reactivate [7][8][9] or persist in immunocompromised patients, such as allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients and cause a persistent anemia related to long-lasting PRCA. Other clinical manifestations have been described among immunocompromised patients, such as myocarditis, hepatitis, pneumonitis and central nervous system (CNS) manifestations.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study

Sammut,

Feghoul,

Xhaard

et al. 2023

Transplant Infectious Dis

View full text Add to dashboard Cite

BackgroundHuman parvovirus B19 (B19V) infection is associated with pure red cell aplasia (PRCA) in immunocompromised patients; however, the spectrum of manifestations associated with B19V in allogeneic hematopoietic stem cell transplantation recipients (alloHSCT) has rarely been reported.MethodsIn this study, we aimed to report clinical and immune features of B19V infection after alloHSCT. We retrospectively collected and analyzed clinical and microbiological data of all transplanted patients with B19V DNAmia or tissue infection detected by polymerase chain reaction (PCR) in our center from 2010 to 2021.ResultsWe report 35 cases of B19V infections in 33 patients. Median time from transplant to B19V first PCR positivity was 6.9 months (interquartile range (IQR) [1.6–18.9]). No preferential immune profile, type of transplantation or conditioning was identified. Hematological impairment was the most frequent sign, followed by rash and fever. Unconventional clinical forms were also detected, such as acute myelitis and myositis. For some cases, the direct relationship between symptoms and B19V infection was difficult to prove but was suggested by targeted tissue PCR positivity. When hematological impairment was not at the forefront, reticulocytopenia helped to diagnose B19V infections. Treatment was mainly based on high dose intravenous immunoglobulin.ConclusionAlthough hematological impairment was the most frequent sign, B19V can affect multiple targets and lead to atypical manifestations. Because of its heterogeneous clinical presentation, B19V infection is likely under‐diagnosed. Diagnosis of unusual B19V organ involvement needs combination of arguments which can include targeted tissue PCR. image

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study

Sammut,

Feghoul,

Xhaard

et al. 2023

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

Transcription-associated mutational pressure in the Parvovirus B19 genome: Reactivated genomes contribute to the variability of viral populations

Khrustalev

Ermalovich

Hübschen

et al. 2017

Journal of Theoretical Biology

View full text Add to dashboard Cite

A Severe Refractory Anaemia and Fever of Unknow Origin: Human Parvovirus B19 Reactivation

Escobar-Sevilla

Merlo

Martínez

et al. 2020

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

Reactivation of human parvovirus B19 is exceptional and characteristic of immunosuppression, with anaemia being the predominant manifestation although pancytopenia and thrombotic microangiopathy may also occur. We describe a patient with a history of diffuse large B-cell lymphoma with pure erythrocyte aplasia due to reactivation of parvovirus B19, who was treated with corticosteroids and immunoglobulins.

show abstract

Réactivation d’une infection à parvovirus B19 chez une patiente infectée par le VIH

Cited by 7 publications

References 13 publications

Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study

Clinical and immune features of human parvovirus B19 infection in allogeneic stem cell transplantation recipients: A retrospective monocentric study

Transcription-associated mutational pressure in the Parvovirus B19 genome: Reactivated genomes contribute to the variability of viral populations

A Severe Refractory Anaemia and Fever of Unknow Origin: Human Parvovirus B19 Reactivation

Contact Info

Product

Resources

About